Trial Profile
Evaluation of safety and efficacy of Peginterferon, Ribavirin, and Boceprevir triple therapy for the treatment of patients with hepatitis c genotype 1 with severe fibrosis in Spanish early access program
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon alfa-2a; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 18 Dec 2015 New trial record